Nature 547, 217–221 (2017); doi:https://doi.org/10.1038/nature22991
In this Letter, the ‘Data availability’ section in the Methods should state ‘WES and RNA-seq data are deposited in dbGaP (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001451.v1.p1). All other data are available from the corresponding author upon reasonable request.’ instead of ‘All data are available from the corresponding author upon reasonable request’. In addition, the ‘Competing interests’ statement should include: ‘C.J.W. is subject to a conflict of interest management plan for the reported studies because of her competing financial interests in Neon Therapeutics. Under this plan, C.J.W. may not access identifiable human subjects’ data nor otherwise participate directly in the IRB-approved protocol reported herein. C.J.W.’s contributions to the overall program strategy and data analyses occurred on a de-identified basis.’ These errors have been corrected in the online versions of the Letter.
Additional information
The online version of the original article can be found at https://doi.org/10.1038/nature22991
Rights and permissions
About this article
Cite this article
Ott, P., Hu, Z., Keskin, D. et al. Correction: Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 555, 402 (2018). https://doi.org/10.1038/nature25145
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature25145
This article is cited by
-
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Signal Transduction and Targeted Therapy (2022)
-
Acquired resistance to cancer immunotherapy
Seminars in Immunopathology (2019)
-
Inactivation of DNA repair—prospects for boosting cancer immune surveillance
Genome Medicine (2018)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.